All In Biotech

Drugs by condition

Drugs approved for duchenne muscular dystrophy

Brand-name prescription drugs and biologics whose FDA label lists duchenne muscular dystrophy as an approved use. Matched on the label phrases: "Duchenne".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

8

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

8

New molecular entities and new biologics

In development

14

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for duchenne muscular dystrophy.

  • Duvyzat (Givinostat Hydrochloride) · Italfarmaco Spa NovelPriority reviewOrphanMar 21, 2024
  • Agamree (Vamorolone) · Catalyst Pharms NovelOrphanOct 26, 2023
  • Amondys 45 (Casimersen) · Sarepta Theraps INC NovelAccelerated approvalPriority reviewOrphanFeb 25, 2021
  • Viltepso (Viltolarsen) · Nippon Shinyaku NovelAccelerated approvalPriority reviewOrphanAug 12, 2020
  • Vyondys 53 (Golodirsen) · Sarepta Theraps INC NovelAccelerated approvalPriority reviewOrphanDec 12, 2019

All approved drugs for duchenne muscular dystrophy, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 12 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Antisense Oligonucleotide (3)

  • Amondys 45 Casimersen · Sarepta Theraps INC · 2021
  • Vyondys 53 Golodirsen · Sarepta Theraps INC · 2019
  • Exondys 51 Eteplirsen · Sarepta Theraps INC · 2016

Corticosteroid (2)

  • Emflaza Deflazacort · Ptc Therap · 2017
  • Emflaza Deflazacort · Ptc Therap · 2017

Histone Deacetylase Inhibitor (1)

  • Duvyzat Givinostat Hydrochloride · Italfarmaco Spa · 2024

Class not listed in FDA's data (2)

  • Agamree Vamorolone · Catalyst Pharms · 2023
  • Viltepso Viltolarsen · Nippon Shinyaku · 2020

Drugs in development for duchenne muscular dystrophy

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • AOC 1044Phase 33 trials

    Avidity Biosciences, Inc. · DMD, Duchenne Muscular Dystrophy, Exon 44

  • DeramiocelCAP-1002, Allogeneic Cardiosphere-Derived CellsPhase 32 trials

    Capricor Inc. · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic

  • SGT-003Phase 32 trials

    Solid Biosciences Inc. · Duchenne Muscular Dystrophy, Advanced Solid Tumor

  • Zeleciment RostudirsenDYNE-251Phase 32 trials

    Dyne Therapeutics · Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD)

  • SevasemtenPhase 24 trials

    Edgewise Therapeutics, Inc. · Becker Muscular Dystrophy, Duchenne Muscular Dystrophy

  • BrogidirsenNS-089, NCNP-02Phase 23 trials

    NS Pharma, Inc. · Duchenne Muscular Dystrophy, Exon 44, DMD

  • BMN 351Phase 22 trials

    BioMarin · Duchenne Muscular Dystrophy (DMD), Duchenne Muscular Dystrophy

  • ENTR-601-44Phase 22 trials

    Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)

  • ENTR-601-45Phase 22 trials

    Entrada Therapeutics, Inc. · Duchenne Muscular Dystrophy (DMD)

  • SAT-3247Phase 22 trials

    Satellos Bioscience, Inc. · Duchenne Muscular Dystrophy, Duchenne, DMD

  • WVE-N531Phase 22 trials

    Wave Life Sciences USA, Inc. · Duchenne Muscular Dystrophy

  • NS-050NCNP-03Phase 21 trial

    NS Pharma, Inc. · Duchenne Muscular Dystrophy

  • RenadirsenDS-5141bPhase 21 trial

    Daiichi Sankyo · Duchenne Muscular Dystrophy

  • RinvaterceptKER-065Phase 21 trial

    Keros Therapeutics, Inc. · Duchenne Muscular Dystrophy

More on duchenne muscular dystrophy: recruiting trials · published research

Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Spinal muscular atrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.